Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
Latest newsMore news →
Sumitomo Pharma announced that an iPS-cell-derived Parkinson’s disease treatment, Amchepri, was transplanted into a patient for the first time in clinical practice after its conditional and time-limited approval.6h agoSumitomo Pharma forecast revenue for the fiscal year ending March 2027 to rise 25% to ¥565 billion and operating profit to fall 3% to ¥104 billion, raising both forecasts.7h agoSumitomo Pharma revised its full-year net profit forecast for the fiscal year ending March 2027 upward by 22.1% to ¥94.0 billion.9h ago